Boston Scientific Announces Long-term Safety and Effectiveness of Bronchial Thermoplasty Demonstrated in Treating Severe Asthma

Boston Scientific Corporation BSX today announced long-term safety data from the Research in Severe Asthma Trial, which demonstrated the maintenance of stable lung function and the absence of clinical complications over a five-year period in patients with severe refractory asthma treated with its Alair® Bronchial Thermoplasty System. The RISA Trial is the third in a series of clinical trials that have completed five years of follow-up for patients treated with bronchial thermoplasty. Results were presented at the annual meeting of the American Thoracic Society in Denver by Ian Pavord, M.D., Professor of Medicine at the University of Leicester, UK and RISA Trial Principal Investigator.